Last 12 months
Inside the activity.
0 purchase rows · 36 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 30 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2023 Filed Feb 10, 2023 22:00 UTC |
Hunt NimrataExecutive Vice President
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 706 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001567619-23-002390 · doc1.xml · derivative · entry 7 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 706 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: Grant of option to buy 1,043 shares of Issuer common stock that vested as to 337 shares on February 14, 2021 and tthe remainder on February 14, 2022. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 22:00 UTC |
Hunt NimrataExecutive Vice President
|
Exercise / conversionCommon Stock | 706 | $141.60 | $99,969.60 |
DisclosureSEC source: 0001567619-23-002390 · doc1.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,463.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 55 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:01 UTC |
Turner Kathy VSenior Vice President
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,000 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-23-002572 · doc1.xml · derivative · entry 4 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,736 Underlying: Common Stock · 1,000 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:01 UTC |
Turner Kathy VSenior Vice President
|
SaleCommon Stock | 1,000 | $505.04 | $505,037.40 |
DisclosureSEC source: 0001567619-23-002572 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,940.8492 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $505.00 to a high of $505.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:01 UTC |
Turner Kathy VSenior Vice President
|
Exercise / conversionCommon Stock | 1,000 | $79.54 | $79,540.00 |
DisclosureSEC source: 0001567619-23-002572 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,940.8492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 17.4623 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2022. Read SEC document |
| February 09, 2023 Filed Feb 16, 2023 23:50 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 21,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003216 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,520 Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:05 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 5,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-002399 · doc1.xml · nonDerivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 6,700 F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:05 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 370 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-002399 · doc1.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 0 Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:05 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 371 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-002399 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 370 Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:05 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 5,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-002399 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 741 F1 · ownership.nature: The reporting person is the settlor and trustee of the 2021 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:04 UTC |
Underberg Sharon E.EVP, GC & Corp. Secretary
|
GrantRestricted Stock Unit · Derivative | 704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002397 · doc1.xml · derivative · entry 4 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,207 Underlying: Common Stock · 704 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:04 UTC |
Underberg Sharon E.EVP, GC & Corp. Secretary
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 201 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002397 · doc1.xml · derivative · entry 3 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2033-02-07 F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:04 UTC |
Underberg Sharon E.EVP, GC & Corp. Secretary
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 4,949 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002397 · doc1.xml · derivative · entry 2 Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,949 Underlying: Common Stock · 4,949 shares Expires 2033-02-07 F5 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:04 UTC |
Smith Martin AlexanderExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002396 · doc1.xml · derivative · entry 4 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,995 Underlying: Common Stock · 754 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:04 UTC |
Smith Martin AlexanderExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 201 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002396 · doc1.xml · derivative · entry 3 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2033-02-07 F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:04 UTC |
Smith Martin AlexanderExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 5,316 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002396 · doc1.xml · derivative · entry 2 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,316 Underlying: Common Stock · 5,316 shares Expires 2033-02-07 F5 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:03 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002395 · doc1.xml · derivative · entry 4 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 880 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:03 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 201 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002395 · doc1.xml · derivative · entry 3 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2033-02-07 F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:03 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 6,236 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002395 · doc1.xml · derivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,236 Underlying: Common Stock · 6,236 shares Expires 2033-02-07 F5 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
GrantRestricted Stock Unit · Derivative | 1,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002394 · doc1.xml · derivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,824 Underlying: Common Stock · 1,231 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 201 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002394 · doc1.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2033-02-07 F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 8,811 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002394 · doc1.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,811 Underlying: Common Stock · 8,811 shares Expires 2033-02-07 F5 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 4,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002393 · doc1.xml · derivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,388 Underlying: Common Stock · 4,398 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F6 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 201 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002393 · doc1.xml · derivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2033-02-07 F6 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
GrantPremium Non-Qualified Stock Option (right-to-buy) · Derivative | 12,181 | Not disclosed Strike: $572.04 | Not disclosed |
DisclosureSEC source: 0001567619-23-002393 · doc1.xml · derivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,181 Underlying: Common Stock · 12,181 shares Expires 2033-02-07 F6 · price: Not applicable. F3 · derivative.exercise_date: Grant of option at a 115% premium to the closing price of Issuer common stock on the NASDAQ Global Select Market on February 8, 2023 to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 21,256 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002393 · doc1.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,256 Underlying: Common Stock · 21,256 shares Expires 2033-02-07 F6 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:01 UTC |
Lane MichaelExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002392 · doc1.xml · derivative · entry 5 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,082 Underlying: Common Stock · 880 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F6 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:01 UTC |
Lane MichaelExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 201 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002392 · doc1.xml · derivative · entry 4 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2033-02-07 F6 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:01 UTC |
Lane MichaelExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 6,236 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002392 · doc1.xml · derivative · entry 3 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,236 Underlying: Common Stock · 6,236 shares Expires 2033-02-07 F6 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:00 UTC |
Johnson Michael PerkinsSenior Vice President
|
GrantRestricted Stock Unit · Derivative | 704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002391 · doc1.xml · derivative · entry 4 Johnson Michael Perkins · CIK 0001917747 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,086 Underlying: Common Stock · 704 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:00 UTC |
Johnson Michael PerkinsSenior Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 804 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002391 · doc1.xml · derivative · entry 3 Johnson Michael Perkins · CIK 0001917747 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804 Underlying: Common Stock · 804 shares Expires 2033-02-07 F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:00 UTC |
Johnson Michael PerkinsSenior Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 4,346 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002391 · doc1.xml · derivative · entry 2 Johnson Michael Perkins · CIK 0001917747 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,346 Underlying: Common Stock · 4,346 shares Expires 2033-02-07 F5 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:00 UTC |
Hunt NimrataExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 829 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002390 · doc1.xml · derivative · entry 6 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,360 Underlying: Common Stock · 829 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F7 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:00 UTC |
Hunt NimrataExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 1,508 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002390 · doc1.xml · derivative · entry 5 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,531 Underlying: Common Stock · 1,508 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in one installment on February 14, 2026. F7 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in one installment on February 14, 2026. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in one installment on February 14, 2026. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:00 UTC |
Hunt NimrataExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 201 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002390 · doc1.xml · derivative · entry 4 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2033-02-07 F7 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:00 UTC |
Hunt NimrataExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 5,868 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002390 · doc1.xml · derivative · entry 3 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,868 Underlying: Common Stock · 5,868 shares Expires 2033-02-07 F7 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 22:00 UTC |
JUNIUS DANIEL MDirector
|
GrantCommon Stock | 14 | $482.95 | $6,761.30 |
DisclosureSEC source: 0001567619-23-001663 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,982 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($6,562.50) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| December 14, 2022 Filed Dec 6, 2022 22:00 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-021350 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,020 Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:30 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 3,046 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001567619-22-021390 · doc1.xml · derivative · entry 3 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,046 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 3,046 shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of shareholders, whichever event was earlier. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:30 UTC |
JUNIUS DANIEL MDirector
|
SaleCommon Stock | 3,046 | $424.91 | $1,294,275.86 |
DisclosureSEC source: 0001567619-22-021390 · doc1.xml · nonDerivative · entry 2 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,968 Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:30 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionCommon Stock | 3,046 | $160.28 | $488,212.88 |
DisclosureSEC source: 0001567619-22-021390 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 22:01 UTC |
SZOSTAK M ANNEDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 2,000 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001567619-22-021351 · doc1.xml · derivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,046 Underlying: Common Stock · 2,000 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 3,046 shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of shareholders, whichever event was earlier. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 22:01 UTC |
SZOSTAK M ANNEDirector
|
SaleCommon Stock | 740 | $428.55 | $317,127.00 |
DisclosureSEC source: 0001567619-22-021351 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 22:01 UTC |
SZOSTAK M ANNEDirector
|
Exercise / conversionCommon Stock | 2,000 | $160.28 | $320,560.00 |
DisclosureSEC source: 0001567619-22-021351 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:00 UTC |
Turner Kathy VSenior Vice President
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 3,000 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001567619-22-021284 · doc1.xml · derivative · entry 4 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,386 Underlying: Common Stock · 3,000 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 10,386 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2018. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:00 UTC |
Turner Kathy VSenior Vice President
|
SaleCommon Stock | 3,000 | $436.00 | $1,308,000.00 |
DisclosureSEC source: 0001567619-22-021284 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,923.3869 Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:00 UTC |
Turner Kathy VSenior Vice President
|
Exercise / conversionCommon Stock | 3,000 | $141.60 | $424,800.00 |
DisclosureSEC source: 0001567619-22-021284 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,923.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,998 | Not disclosed Strike: $62.00 | Not disclosed |
DisclosureSEC source: 0001567619-22-020466 · doc1.xml · derivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,998 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 9,499 shares of Issuer common stock that became exercisable for 8,244 shares in four equal annual installments beginning February 14, 2015 and for the remaining 1,255 shares on February 14, 2019 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
SaleCommon Stock | 600 | $435.88 | $261,526.50 |
DisclosureSEC source: 0001567619-22-020466 · doc1.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,804.6426 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $435.77 to a high of $436.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
SaleCommon Stock | 2,543 | $435.07 | $1,106,386.06 |
DisclosureSEC source: 0001567619-22-020466 · doc1.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,404.6426 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $434.70 to a high of $435.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.